Published in World J Gastroenterol on November 21, 2006
Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology (2011) 5.06
Spontaneous evolution in bilirubin levels predicts liver-related mortality in patients with alcoholic hepatitis. PLoS One (2014) 1.39
A meta-analysis of nutritional supplementation for management of hospitalized alcoholic hepatitis. Can J Gastroenterol (2012) 0.85
Molecular targets in the treatment of alcoholic hepatitis. World J Gastroenterol (2012) 0.82
Focus on: Alcohol and the liver. Alcohol Res Health (2010) 0.80
Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome? World J Gastroenterol (2009) 0.79
Alcoholic hepatitis. J Med Life (2013) 0.78
Pentoxifylline Plus Prednisolone versus Pentoxifylline Only for Severe Alcoholic Hepatitis: A Randomized Controlled Clinical Trial. Ann Med Health Sci Res (2014) 0.77
Alcoholic hepatitis and HCV interactions in the modulation of liver disease. J Viral Hepat (2015) 0.76
Management of alcoholic hepatitis. Gastroenterol Hepatol (N Y) (2007) 0.75
Alcoholic Hepatitis and Intestinal Barrier Breakdown: A Theoretical Reappraisal Based on Pentoxifylline's Action. Gastroenterology Res (2009) 0.75
Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials (1996) 64.38
Transection of the oesophagus for bleeding oesophageal varices. Br J Surg (1973) 26.26
Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet (1998) 19.31
A model to predict survival in patients with end-stage liver disease. Hepatology (2001) 18.06
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med (2000) 16.20
Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists. Control Clin Trials (1995) 9.85
A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology (2000) 9.74
Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc (1980) 8.36
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Methylprednisolone therapy in patients with severe alcoholic hepatitis. A randomized multicenter trial. Ann Intern Med (1989) 4.07
Burden of liver disease in the United States: summary of a workshop. Hepatology (2002) 4.00
Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology (2000) 3.97
Corticosteroid therapy of alcoholic hepatitis. Gastroenterology (1978) 3.21
Alcohol as a risk factor for global burden of disease. Eur Addict Res (2003) 3.11
A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology (2004) 3.04
MELD accurately predicts mortality in patients with alcoholic hepatitis. Hepatology (2005) 2.99
Alcohol-attributable deaths and years of potential life lost--United States, 2001. MMWR Morb Mortal Wkly Rep (2004) 2.81
Determinants of progression to cirrhosis or fibrosis in pure alcoholic fatty liver. Lancet (1995) 2.64
Analysis of factors predictive of mortality in alcoholic hepatitis and derivation and validation of the Glasgow alcoholic hepatitis score. Gut (2005) 2.62
The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med (1996) 2.60
Cytokines in alcoholic liver disease. Semin Liver Dis (1999) 2.37
Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med (1989) 2.28
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis. J Hepatol (2005) 2.21
Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol (2004) 2.16
S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol (1999) 2.14
Prognostic value of Child-Turcotte criteria in medically treated cirrhosis. Hepatology (1984) 1.95
Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo End-stage Liver Disease. Hepatology (2001) 1.94
Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol (2002) 1.83
A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis. Am J Gastroenterol (2004) 1.83
Antibodies to hepatitis B virus and hepatitis C virus in alcoholic hepatitis and cirrhosis: their prevalence and clinical relevance. The VA Cooperative Study Group (No. 119) Hepatology (1991) 1.78
A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med (1992) 1.71
Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med (1990) 1.60
Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol (2003) 1.45
S-adenosyl-L-methionine attenuates alcohol-induced liver injury in the baboon. Hepatology (1990) 1.39
Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med (1990) 1.38
Abnormal hepatic methionine and glutathione metabolism in patients with alcoholic hepatitis. Alcohol Clin Exp Res (2004) 1.37
Feeding S-adenosyl-L-methionine attenuates both ethanol-induced depletion of mitochondrial glutathione and mitochondrial dysfunction in periportal and perivenous rat hepatocytes. Hepatology (1995) 1.35
Morphology of alcoholic liver disease. Clin Liver Dis (2005) 1.34
Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone. N Engl J Med (1984) 1.30
Medium and long chain fat absorption in patients with cirrhosis. J Clin Invest (1966) 1.29
Early perivenular sclerosis in alcoholic fatty liver: an index of progressive liver injury. Gastroenterology (1977) 1.28
Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med (1984) 1.26
Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology (2003) 1.26
Survival and prognostic factors in patients with severe alcoholic hepatitis treated with prednisolone. Gastroenterology (1996) 1.26
Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial. Hepatology (2000) 1.23
Nutrition and alcoholic liver disease. Semin Liver Dis (2004) 1.22
Alcoholic hepatitis. Natural history and evaluation of prednisolone therapy. Ann Intern Med (1971) 1.21
Controlled trial of methylprednisolone therapy in severe acute alcoholic hepatitis. Gut (1982) 1.19
S-adenosyl-L-methionine: its role in the treatment of liver disorders. Am J Clin Nutr (2002) 1.16
Colchicine treatment of alcoholic cirrhosis: a randomized, placebo-controlled clinical trial of patient survival. Gastroenterology (2005) 1.15
Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. J Hepatol (1996) 1.15
Diagnosis and therapy of alcoholic liver disease. Semin Liver Dis (2004) 1.13
Glucocorticoids are ineffective in alcoholic hepatitis: a meta-analysis adjusting for confounding variables. Gut (1995) 1.13
The role of tumor necrosis factor-alpha in acute endotoxin-induced hepatotoxicity in ethanol-fed rats. Hepatology (1994) 1.12
Prednisolone and testosterone propionate in cirrhosis of the liver. A controlled trial. Lancet (1960) 1.11
Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol (2002) 1.11
Double-blind controlled trial of prednisolone therapy in patients with severe acute alcoholic hepatitis and spontaneous encephalopathy. Gastroenterology (1980) 1.11
A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study. Hepatology (1993) 1.10
Retrospective analysis of 18 cases of antithyroid drug (ATD)-induced agranulocytosis. Endocr J (2002) 1.10
Plasma tumor necrosis factor alpha predicts decreased long-term survival in severe alcoholic hepatitis. Alcohol Clin Exp Res (1990) 1.10
Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease. Gastroenterology (1979) 1.08
VA cooperative study on alcoholic hepatitis. II: Prognostic significance of protein-calorie malnutrition. Am J Clin Nutr (1986) 1.07
Experimental alcohol-induced hepatic necrosis: suppression by propylthiouracil. Proc Natl Acad Sci U S A (1975) 1.06
Protein energy malnutrition in severe alcoholic hepatitis: diagnosis and response to treatment. The VA Cooperative Study Group #275. JPEN J Parenter Enteral Nutr (1996) 1.06
S-adenosylmethionine protects against acetaminophen hepatotoxicity in two mouse models. Hepatology (1992) 1.06
Fulminant hepatic failure associated with propylthiouracil. Ann Pharmacother (2003) 1.06
Long-term treatment of alcoholic liver disease with propylthiouracil. N Engl J Med (1987) 1.06
Alcoholism is associated with hepatitis C but not hepatitis B in an urban population. Am J Gastroenterol (1996) 1.05
Relationship of protein calorie malnutrition to alcoholic liver disease: a reexamination of data from two Veterans Administration Cooperative Studies. Alcohol Clin Exp Res (1995) 1.05
Role of S-adenosyl-L-methionine in the treatment of liver diseases. J Hepatol (1999) 1.05
Epidemiology of hepatitis C among veterans with alcoholic liver disease. The VA Cooperative Study Group 275. Am J Gastroenterol (1993) 1.04
The role of the discriminant factor in the assessment and treatment of alcoholic hepatitis. J Clin Gastroenterol (2004) 1.02
Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial. N Engl J Med (1971) 0.99
Prognosis of alcoholic cirrhosis in the presence and absence of alcoholic hepatitis. Gastroenterology (1987) 0.98
Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol (2001) 0.97
Propylthiouracil-induced severe hepatitis: a case report and review of the literature. J Gastroenterol (1998) 0.96
Young v adult cirrhotics: a prospective, comparative analysis of the clinical profile, natural course and survival. Gut (1988) 0.96
Propylthiouracil-induced fatal hepatic necrosis. Am J Gastroenterol (1987) 0.96
Perivenular fibrosis as precursor lesion of cirrhosis. JAMA (1985) 0.95
Fulminant hepatitis and lymphocyte sensitization due to propylthiouracil. Gastroenterology (1976) 0.95
Adrenocorticosteroid therapy in alcoholic hepatitis. A prospective, double-blind randomized study. Am J Dig Dis (1977) 0.95
A controlled trial of 6-methylprednisolone in acute alcoholic hepatitis. With a note on published results in encephalopathic patients. Am J Gastroenterol (1978) 0.93
Prednisone therapy of acute alcoholic hepatitis. Report of a controlled trial. Ann Intern Med (1973) 0.92
Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology (1978) 0.91
Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis. Gastroenterology (1982) 0.90
Aminoacid therapy of alcoholic hepatitis. Lancet (1980) 0.88
VA Cooperative Study on Alcoholic Hepatitis. III: Changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy. JPEN J Parenter Enteral Nutr (1985) 0.87
"Nonalcoholic" chronic hepatitis in the alcoholic. Gastroenterology (1977) 0.86
Low-grade steatosis and major changes in portal flow as new prognostic factors in steroid-treated alcoholic hepatitis. Hepatology (2004) 0.86
Controlled trial of nutritional supplementation, with and without branched chain amino acid enrichment, in treatment of acute alcoholic hepatitis. J Hepatol (1985) 0.85
Colchicine for alcoholic and non-alcoholic liver fibrosis and cirrhosis. Cochrane Database Syst Rev (2005) 0.85
Serum free proline and free hydroxyproline in patients with chronic liver disease. Gastroenterology (1975) 0.84
Elevation of serum interleukin 8 levels in acetaminophen overdose in children and adolescents. Clin Pharmacol Ther (2001) 0.84
Effect of parenteral amino acid supplementation in alcoholic hepatitis. Hepatology (1985) 0.84
Corticosteroids for alcoholic hepatitis--what's next? J Hepatol (2005) 0.84
Alcoholic hepatitis: from pathogenesis to treatment. Curr Med Res Opin (2005) 0.84
Antibody to hepatitis C is common among patients with alcoholic liver disease with and without risk factors. Am J Gastroenterol (1991) 0.83
Failure of colchicine to improve short-term survival in patients with alcoholic hepatitis. Gastroenterology (1990) 0.83
Hyperalimentation in alcoholic hepatitis. Am J Gastroenterol (1979) 0.83
c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology (2006) 3.76
Neutrophil depletion protects against murine acetaminophen hepatotoxicity. Hepatology (2006) 3.70
Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA (2006) 3.49
Betaine decreases hyperhomocysteinemia, endoplasmic reticulum stress, and liver injury in alcohol-fed mice. Gastroenterology (2003) 3.18
Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J Biol Chem (2008) 3.08
Clinical risk factors for portopulmonary hypertension. Hepatology (2008) 2.62
Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology (2004) 2.26
Outcome of acute idiosyncratic drug-induced liver injury: Long-term follow-up in a hepatotoxicity registry. Hepatology (2006) 2.12
Drug-induced liver injury. Drug Saf (2007) 1.99
Predominant role of sterol response element binding proteins (SREBP) lipogenic pathways in hepatic steatosis in the murine intragastric ethanol feeding model. J Hepatol (2006) 1.89
Sensitivity of the 2-oxoglutarate carrier to alcohol intake contributes to mitochondrial glutathione depletion. Hepatology (2003) 1.72
Hyperhomocysteinemia, endoplasmic reticulum stress, and alcoholic liver injury. World J Gastroenterol (2004) 1.68
Effect of glutathione depletion on sites and topology of superoxide and hydrogen peroxide production in mitochondria. Mol Pharmacol (2003) 1.62
Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. Am J Physiol Gastrointest Liver Physiol (2006) 1.62
ASMase is required for chronic alcohol induced hepatic endoplasmic reticulum stress and mitochondrial cholesterol loading. J Hepatol (2013) 1.61
ER stress: can the liver cope? J Hepatol (2006) 1.58
c-Jun N-terminal kinase (JNK)-dependent acute liver injury from acetaminophen or tumor necrosis factor (TNF) requires mitochondrial Sab protein expression in mice. J Biol Chem (2011) 1.57
Glutathione in liver diseases and hepatotoxicity. Mol Aspects Med (2008) 1.55
Serum alanine aminotransferase in skeletal muscle diseases. Hepatology (2005) 1.54
Hepatic mitochondrial glutathione: transport and role in disease and toxicity. Toxicol Appl Pharmacol (2005) 1.54
Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next? Hepatology (2004) 1.51
Impact of hepatopulmonary syndrome on quality of life and survival in liver transplant candidates. Gastroenterology (2008) 1.50
The contribution of endoplasmic reticulum stress to liver diseases. Hepatology (2011) 1.50
Role of CHOP in hepatic apoptosis in the murine model of intragastric ethanol feeding. Alcohol Clin Exp Res (2005) 1.49
Role of S-adenosylmethionine, folate, and betaine in the treatment of alcoholic liver disease: summary of a symposium. Am J Clin Nutr (2007) 1.49
Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med (2009) 1.44
Immune-mediated drug-induced liver disease. Clin Liver Dis (2002) 1.38
Regulation of mitochondrial glutathione redox status and protein glutathionylation by respiratory substrates. J Biol Chem (2010) 1.37
Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology (2009) 1.35
Role of innate immunity in acetaminophen-induced hepatotoxicity. Expert Opin Drug Metab Toxicol (2006) 1.35
Role of TNF-alpha in ethanol-induced hyperhomocysteinemia and murine alcoholic liver injury. Hepatology (2004) 1.31
Liver-specific loss of glucose-regulated protein 78 perturbs the unfolded protein response and exacerbates a spectrum of liver diseases in mice. Hepatology (2011) 1.23
Silencing glycogen synthase kinase-3beta inhibits acetaminophen hepatotoxicity and attenuates JNK activation and loss of glutamate cysteine ligase and myeloid cell leukemia sequence 1. J Biol Chem (2010) 1.20
Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. Hepatology (2003) 1.19
Redox regulation of tumor necrosis factor signaling. Antioxid Redox Signal (2009) 1.18
Signal transduction pathways involved in drug-induced liver injury. Handb Exp Pharmacol (2010) 1.16
Mechanisms of drug-induced liver disease. Clin Liver Dis (2007) 1.15
Acetaldehyde impairs mitochondrial glutathione transport in HepG2 cells through endoplasmic reticulum stress. Gastroenterology (2003) 1.14
Reduced glutathione depletion causes necrosis and sensitization to tumor necrosis factor-alpha-induced apoptosis in cultured mouse hepatocytes. Hepatology (2002) 1.13
Marked elevation in serum transaminases: an atypical presentation of choledocholithiasis. Am J Gastroenterol (2005) 1.12
Mitochondrial glutathione: features, regulation and role in disease. Biochim Biophys Acta (2012) 1.11
Hydrogen peroxide and redox modulation sensitize primary mouse hepatocytes to TNF-induced apoptosis. Free Radic Biol Med (2006) 1.11
Mechanism of staurosporine-induced apoptosis in murine hepatocytes. Am J Physiol Gastrointest Liver Physiol (2002) 1.10
Differences in betaine-homocysteine methyltransferase expression, endoplasmic reticulum stress response, and liver injury between alcohol-fed mice and rats. Hepatology (2010) 1.08
Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria. Trends Pharmacol Sci (2013) 1.07
Mechanisms of protection by the betaine-homocysteine methyltransferase/betaine system in HepG2 cells and primary mouse hepatocytes. Hepatology (2007) 1.05
Clinical perspectives on xenobiotic-induced hepatotoxicity. Drug Metab Rev (2004) 1.05
Hepatic reactions during treatment of multiple sclerosis with interferon-beta-1a: incidence and clinical significance. Drug Saf (2003) 1.03
Regulation of H(2)O(2)-induced necrosis by PKC and AMP-activated kinase signaling in primary cultured hepatocytes. Am J Physiol Cell Physiol (2008) 1.01
Mechanisms of pathogenesis in drug hepatotoxicity putting the stress on mitochondria. Mol Interv (2010) 1.00
Metabonomic investigation of liver profiles of nonpolar metabolites obtained from alcohol-dosed rats and mice using high mass accuracy MSn analysis. J Proteome Res (2010) 1.00
Dynamic adaptation of liver mitochondria to chronic alcohol feeding in mice: biogenesis, remodeling, and functional alterations. J Biol Chem (2012) 0.99
Mechanisms of drug-induced liver injury. Clin Liver Dis (2013) 0.99
Role of cAMP-responsive element-binding protein (CREB)-regulated transcription coactivator 3 (CRTC3) in the initiation of mitochondrial biogenesis and stress response in liver cells. J Biol Chem (2011) 0.98
Usnic acid-induced necrosis of cultured mouse hepatocytes: inhibition of mitochondrial function and oxidative stress. Biochem Pharmacol (2004) 0.98
Glutathione depletion down-regulates tumor necrosis factor alpha-induced NF-kappaB activity via IkappaB kinase-dependent and -independent mechanisms. J Biol Chem (2007) 0.97
Effect of transgenic extrahepatic expression of betaine-homocysteine methyltransferase on alcohol or homocysteine-induced fatty liver. Alcohol Clin Exp Res (2008) 0.97
Avoiding idiosyncratic DILI: two is better than one. Hepatology (2013) 0.93
Mitochondrial GSH determines the toxic or therapeutic potential of superoxide scavenging in steatohepatitis. J Hepatol (2012) 0.93
Current challenges and controversies in drug-induced liver injury. Drug Saf (2012) 0.90
Interstrain differences in liver injury and one-carbon metabolism in alcohol-fed mice. Hepatology (2012) 0.89
The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future. Drug Saf (2014) 0.87
Severe hepatotoxicity associated with the use of weight loss diet supplements containing ma huang or usnic acid. J Hepatol (2004) 0.87
How to protect against acetaminophen: don't ask for JUNK. Gastroenterology (2008) 0.87
Drug hepatotoxicity. Clin Liver Dis (2006) 0.86
Liver safety assessment in special populations (hepatitis B, C, and oncology trials). Drug Saf (2014) 0.86
Differential effect of gender on hepatic fat. Pediatr Radiol (2011) 0.83
Respiratory substrates regulate S-nitrosylation of mitochondrial proteins through a thiol-dependent pathway. Chem Res Toxicol (2014) 0.82
Investigation of chronic alcohol consumption in rodents via ultra-high-performance liquid chromatography-mass spectrometry based metabolite profiling. J Chromatogr A (2012) 0.79
Genetic variation in UGT1A1 typical of Gilbert syndrome is associated with unconjugated hyperbilirubinemia in patients receiving tocilizumab. Pharmacogenet Genomics (2011) 0.78
Chelerythrine stimulates GSH transport by rat Mrp2 (Abcc2) expressed in canine kidney cells. Am J Physiol Gastrointest Liver Physiol (2003) 0.78
A murder mystery in the liver: who done it and how? J Clin Invest (2016) 0.76
Did this drug cause my patient's hepatitis? Ann Intern Med (2003) 0.75
Statin-induced hepatotoxicity. Gastroenterology (2004) 0.75
Liver injury associated with the beta-interferons for MS. Neurology (2004) 0.75
The thiol sensitivity of glutathione transport in sidedness-sorted basolateral liver plasma membrane and in Oatp1-expressing HeLa cell membrane. Mol Pharmacol (2002) 0.75